ArticleTranslational lung cancer research2016
S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer.
Article in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Evaluating liquid biopsy biomarkers for early detection of brain metastasis: A systematic review.Neuro-oncology practice · 2025Article
- The immune landscape in brain metastasis.Neuro-oncology · 2025Review
- S100 Protein Family in Lung Cancer: an Updated Narrative Review.Cancer management and research · 2025Review
- Changes in S100 calcium-binding protein β (S100β) and cognitive function from pre- to post-chemotherapy among women with breast cancer.Brain, behavior, & immunity - health · 2024Article
- Review
- Blood Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Promising Screening Biomarkers for Brain Metastases in Patients with Lung Cancer.International journal of molecular sciences · 2024Article
- AI-guided histopathology predicts brain metastasis in lung cancer patients.The Journal of pathology · 2024Article
- The Evolving Landscape of B Cells in Cancer Metastasis.Cancer research · 2023Review
- Liquid biopsies to occult brain metastasis.Molecular cancer · 2022Review
- Prognostic Characteristics of Immune-Related Genes and the Related Regulatory Axis in Patients With Stage N+M0 Breast Cancer.Frontiers in oncology · 2022Article
- Detection of leucine-rich alpha-2-glycoprotein 1 containing immunocomplexes in the plasma of lung cancer patients with epitope-specific mAbs.Cancer biomarkers : section A of Disease markers · 2022Article
- Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease.Cancers · 2021Review
- The role of autoantibody detection in the diagnosis and staging of lung cancer.Annals of translational medicine · 2021Article
- Article
- A Novel S100 Family-Based Signature Associated with Prognosis and Immune Microenvironment in Glioma.Journal of oncology · 2021Article
- Friend or Foe: S100 Proteins in Cancer.Cancers · 2020Review
- S100B as a biomarker for brain metastases in patients with non-small cell lung cancer.Biomedical reports · 2020Article
- Association of S100B polymorphisms and serum S100B with risk of ischemic stroke in a Chinese population.Scientific reports · 2018Article
- Biomarkers in traumatic brain injury (TBI): a review.Neuropsychiatric disease and treatment · 2018Review
- Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundS100B is an astrocytic protein that enters the blood stream when there is disruption of the blood-brain barrier (BBB). Over time, antibodies against S100B develop in the sera of patients who experience persistent or repeated BBB disruptions. We explored the use of serum S100B protein and S100B autoantibodies for the detection of brain metastasis in patients with lung cancer.
methodsOne hundred and twenty eight untreated patients with lung cancer who had brain imaging performed as part of their routine evaluation, participated. Serum S100B protein levels were measured by direct ELISA and S100B autoantibody levels by reverse ELISA. These levels in patients with brain metastases were compared alone and in combination to those without brain metastases.
resultsEighteen (14%) patients had brain metastasis at the time of lung cancer diagnosis. An S100B cutoff of 0.058 ng/mL had a sensitivity of 89% and specificity of 43% for brain metastasis. When an autoantibody threshold of <2.00 absorbance units was used in conjunction with S100B, the sensitivity remained at 89%, and the specificity increased to 58%. The overall accuracy was 51% with S100B alone, improving to 62.5% when combined with autoantibodies.
conclusionsSerum S100B and S100B autoantibody levels may help to identify which lung cancer patients have brain metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.